The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued an updated practice guideline on the treatment of thyroid cancer patients with iodine-131 (I-131) in the October issue of the Journal of Nuclear Medicine.
The guideline is designed to assist trained practitioners in evaluating patients for therapy with I-131 for benign or malignant diseases of the thyroid gland, performing this treatment in a safe and appropriate manner, understanding and evaluating the pathological conditions resulting from the therapy, and reporting the outcomes of therapy.
The document also highlights 14 issues that require further clarification, such as the diagnostic role of alternative imaging agents for thyroid cancer and the frequency and length of long-term follow-up after I-131 therapy.
